Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mandatory Pediatric Rule Has “Strong” Support Of HHS, Thompson Says

Executive Summary

HHS' "strong" support for the mandatory pediatric study rule makes legislative action on the issue unnecessary, Secretary Tommy Thompson told the Senate Appropriations/HHS Subcommittee June 4

You may also be interested in...



Pediatric Exclusivity Expansion Floated On Hill; Mandatory Study Bill Pending

An additional three months of exclusivity would be awarded for a company's second round of pediatric studies under a proposed amendment to Sen. Hillary Rodham Clinton's (D-N.Y.) bill to codify FDA's mandatory pediatric study rule

Pediatric Exclusivity Expansion Floated On Hill; Mandatory Study Bill Pending

An additional three months of exclusivity would be awarded for a company's second round of pediatric studies under a proposed amendment to Sen. Hillary Rodham Clinton's (D-N.Y.) bill to codify FDA's mandatory pediatric study rule

PDUFA III Authorizes FDA To Alert MDs To Failed Phase IV Commitments

FDA will have the authority to require manufacturers to inform prescribers if they fail to complete Phase IV commitments under the Prescription Drug User Fee Act reauthorization

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS039976

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel